Monopar Therapeutics Income Statement (2016-2020) | MNPR

Income Statement Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020
Operating items
Research & Development 0.13M0.31M0.18M0.31M0.46M0.30M0.30M0.52M0.84M0.33M0.22M0.58M
Selling, General & Administrative 0.24M0.28M0.22M0.43M0.44M0.36M0.36M0.41M0.57M0.60M0.54M0.64M
Other Operating Expenses 14.50M
Operating Expenses 0.37M0.59M14.90M0.74M0.90M0.67M0.67M0.93M1.41M0.93M0.76M1.22M
Operating Income -0.37M-0.59M-14.90M-0.74M-0.90M-0.67M-0.67M-0.93M-1.41M-0.93M-0.76M-1.22M
EBIT -0.37M-0.59M-14.90M-0.74M-0.90M-0.67M-0.67M-0.93M-1.41M-0.93M-0.76M-1.22M
Net income details
EBT -0.37M-0.59M-14.90M-0.74M-0.90M-0.67M-0.67M-0.93M-1.41M-0.93M-0.76M-1.22M
Profit After Tax -0.37M-0.59M-14.88M-0.71M-0.88M-0.64M-0.64M-0.89M-1.38M-0.91M-0.74M-1.21M
Income from Continuing Operations -0.37M-0.59M-14.90M-0.74M-0.90M-0.67M-0.67M-0.93M-1.41M-0.93M-0.76M-1.22M
Consolidated Net Income -0.37M-0.59M-14.90M-0.74M-0.90M-0.67M-0.67M-0.93M-1.41M-0.93M-0.76M-1.22M
Income towards Parent Company -0.37M-0.59M-14.90M-0.74M-0.90M-0.67M-0.67M-0.93M-1.41M-0.93M-0.76M-1.22M
Net Income towards Common Stockholders -0.37M-0.59M-14.90M-0.74M-0.90M-0.67M-0.67M-0.93M-1.41M-0.93M-0.76M-1.22M
Additional items
EPS (Basic) -0.04-0.07-1.68-0.05-0.09-0.07-0.07-0.10-0.15-0.10-0.08-0.13
Shares Outstanding (Weighted Average) 1.86M1.86M1.86M1.86M1.86M1.86M1.86M1.86M1.86M1.86M1.86M1.86M2.08M2.12M2.13M2.15M
EBITDA -0.37M-0.37M-14.88M-0.71M-0.88M-0.64M-0.64M-0.89M-1.38M-0.90M-0.74M-1.21M